Posted by Michael Wonder on 29 Nov 2023
eFFECTOR receives US FDA fast track designation for zotatifin in combination with fulvestrant and abemaciclib for treatment of ER positive/HER2 negative advanced metastatic breast cancer
28 November 2023 - Designation is for second or third-line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor.
eFFECTOR Therapeutics today announced that the US FDA has granted fast track designation for zotatifin in combination with fulvestrant and abemaciclib as second- or third-line therapy for the treatment of adult patients with oestrogen receptor-positive/human epidermal growth factor negative advanced or metastatic breast cancer with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor.
